Candesartan Effectiveness Study in Pro-B Type Natriuretic Peptides (BNP)

AstraZeneca

Status and phase: Completed; Phase 4

Conditions: Hypertension; Left Ventricular Hypertrophy

Treatments: Drug: Candesartan; Drug: Felodipine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00348686

D2452L00012

CAP

Details and patient eligibility

About

The purpose of this study is to investigate effect of candesartan based therapy on percent change of B type natriuretic peptides(BNP) level in the subjects with hypertension and left ventricular hypertrophy.

Enrollment: 315 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Hypertension with diastolic blood pressure within 95-115 mm/Hg or/and systolic blood pressure within 160-200 mm/Hg
• Patients diagnosed as left ventricular hypertrophy by electrocardiogram

Exclusion criteria

• Secondary hypertension
• History of myocardial infarction
• Stroke within the previous 6 months

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

315 participants in 1 patient group

Candesartan

Experimental group

Description:

Subjects were treated for 24 weeks with Candesartan 16mg once daily as initial dose. Subjects were modified investigational product dose to Candesartan 32mg, Candesartan 32mg + Felodipine 5mg, Candesartan 32mg + Felodipine 10mg, sequentially according to their blood pressures.

Treatment:

Drug: Candesartan

Drug: Candesartan

Drug: Felodipine

Drug: Felodipine